Bristol Myers Squibb vs Pfizer
Pfizer is the larger business, with $62.58bn of revenue in fiscal 2025 against $48.19bn for Bristol Myers Squibb (1.3 times as much). Bristol Myers Squibb grew faster (-0.2% against -1.6%). Bristol Myers Squibb kept more of each dollar of sales as profit: a net margin of 14.6% against 12.4%.
| Latest fiscal year | Bristol Myers SquibbBMY, 2025 | PfizerPFE, 2025 |
|---|---|---|
| Revenue | $48.19bn | $62.58bn |
| Revenue growth | -0.2% | -1.6% |
| Net income | $7.05bn | $7.77bn |
| Operating margin | — | — |
| Net margin | 14.6% | 12.4% |
| Return on equity | 40.5% | 8.9% |
| Free cash flow | $12.85bn | $9.07bn |
| Cash | $10.21bn | $1.14bn |
| Total debt | $47.09bn | $64.80bn |
| Debt to equity | 254.9% | — |
| Dividend per share | $2.49 | $1.72 |
| Dividend yield | 4.0% | 5.5% |
| Share buybacks | $0 | — |
| Employees | 32,500 | 75,000 |
| Market value | $129.38bn | $174.79bn |
| Price vs our value range | Below our value range | Within our value range |
| Moat score | 77 (Strong) | 78 (Strong) |
| Insider trades, 12 months | 0 buys, 4 sales | 3 buys, 2 sales |